SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-21-144979
Filing Date
2021-04-30
Accepted
2021-04-30 16:05:04
Documents
8

Document Format Files

Seq Description Document Type Size
1 DEFA14A d167870ddefa14a.htm DEFA14A 29953
2 GRAPHIC g167870d2.jpg GRAPHIC 819
3 GRAPHIC g167870g0429033605404.jpg GRAPHIC 2082
4 GRAPHIC g167870g0429033606215.jpg GRAPHIC 942
5 GRAPHIC g167870g0429033606558.jpg GRAPHIC 925
6 GRAPHIC g167870g0429033606839.jpg GRAPHIC 1079
7 GRAPHIC g167870snap0001.jpg GRAPHIC 1373
8 GRAPHIC g167870snap0002.jpg GRAPHIC 1397
  Complete submission text file 0001193125-21-144979.txt   43886
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Filer) CIK: 0001819790 (see all company filings)

IRS No.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39614 | Film No.: 21877783
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences